Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice

NCT06170619 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT06170619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06170619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice
Lead sponsor
Boston Scientific Corporation
Phase
Observational
Overall status
Completed
Start date
June 19, 2024
Completion date
September 9, 2025
Enrollment
125 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bleeding, hemorrhage, hypervascular tumors